StreetInsider.com News Articles

Form 4 IDEXX LABORATORIES INC For: Aug 20 Filed by: Emerson Andrew

Mon, 24 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26968952.html

Form 4 IDEXX LABORATORIES INC For: Aug 20 Filed by: Emerson Andrew

Mon, 24 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26968952.html

IDEXX Laboratories (IDXX) Reiterated at Buy by Stifel as Fundamentals Remain Intact

Thu, 20 Aug 2026 08:13:14 -0400

Stifel analyst Jonathan Block reiterated a Buy rating and $675.00 price target on IDEXX Laboratories (NASDAQ: IDXX).

The analyst commented, "We believe the long-term company fundamentals remain intact. IDEXX is capturing market share across multiple modalities, international momentum is increasing, and diagnostics in the veterinary office will likely continue to play an increasingly important role. Additionally, we believe that IDEXX's innovation portfolio will aid CAG Dx recurring revenue growth in coming years."

For an analyst ratings summary and ratings history on IDEXX Laboratories click here. For more ratings news on IDEXX Laboratories click here.

Shares of IDEXX Laboratories closed at $562.20

IDEXX launches point-of-care cardiac test for cats and dogs

Tue, 11 Aug 2026 07:01:17 -0400

IDEXX Laboratories, Inc. (Nasdaq: IDXX) announced the launch of the Catalyst proBNP Test, which the company claims is the first dual-species, in-clinic test for NT-proBNP, a biomarker used to evaluate heart disease in cats and dogs.

The test will be available on the Catalyst platform, which has a global installed base of nearly 80,000 analyzers, beginning in North America in October 2026, with international availability to follow.

NT-proBNP is used to screen, diagnose, and monitor cardiac disease in companion animals. According to published veterinary guidelines cited in the press release, heart disease affects approximately one in six cats and one in 10

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

Tue, 11 Aug 2026 07:00:00 -0400

New test brings quantitative cardiac assessment for cats and dogs into everyday workflows

WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst™ proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a well-established biomarker used to evaluate heart disease in companion animals, a condition that affects approximately 1 in 6 cats1 and 1 in 10 dogs2, yet remains underassessed in general practice. Available on

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

Tue, 11 Aug 2026 07:00:00 -0400

New test brings quantitative cardiac assessment for cats and dogs into everyday workflows

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

Tue, 11 Aug 2026 07:00:00 -0400

New test brings quantitative cardiac assessment for cats and dogs into everyday workflows

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

Tue, 11 Aug 2026 07:00:00 -0400

New test brings quantitative cardiac assessment for cats and dogs into everyday workflows

IDEXX Laboratories (IDXX) PT Lowered to $710 at Barclays

Tue, 11 Aug 2026 04:07:06 -0400

Barclays analyst Glen Santangelo lowered the price target on IDEXX Laboratories (NASDAQ: IDXX) to $710.00 (from $800.00) while maintaining a Overweight rating.

IDEXX Laboratories (IDXX) PT Raised to $670 at UBS

Wed, 05 Aug 2026 09:19:02 -0400

UBS analyst Andrea Alfonso raised the price target on IDEXX Laboratories (NASDAQ: IDXX) to $670.00 (from $620.00) while maintaining a Neutral rating.

Form 10-Q IDEXX LABORATORIES INC For: Jun 30

Tue, 04 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260804/26866679.html

Form 10-Q IDEXX LABORATORIES INC For: Jun 30

Tue, 04 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260804/26866679.html

Morgan Stanley: 'IDXX Shares Should Rise'

Tue, 04 Aug 2026 08:23:03 -0400

Morgan Stanley: 'IDXX Shares Should Rise'.

The analyst comments "IDXX Shares Should Rise: Solid print across the board, with all-important CAG recurring organic growth of 10.3%, nicely ahead of cons (+9.2%), as well as continuing consumables momentum +15%. Investor focus was also on inVue placements (1,600 units), where it handily exceeded buy-side expectations, which should set the stage for continue CAG strength. It bumped up CAG recurring organic guidance growth by 40bps with further guidance details below. All in, IDXX shares should rise on the latest upside essentially across the board."

Morgan Stanley: 'IDXX Shares Should Rise'

Tue, 04 Aug 2026 08:23:03 -0400

Morgan Stanley: 'IDXX Shares Should Rise'.

IDEXX Labs (IDXX) Tops Q2 EPS by 31c ; Offers Guidance

Tue, 04 Aug 2026 06:34:05 -0400

IDEXX Labs (NASDAQ: IDXX) reported Q2 EPS of $4.27, $0.31 better than the analyst estimate of $3.96. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.2 billion.

GUIDANCE:

IDEXX Labs sees FY2026 EPS of $14.69-$14.94, versus the consensus of $14.66. IDEXX Labs sees FY2026 revenue of $4.7-4.75 billion, versus the consensus of $4.71 billion.

For earnings history and earnings-related data on IDEXX Labs (IDXX) click here.

IDEXX Labs (IDXX) Tops Q2 EPS by 31c ; Offers Guidance

Tue, 04 Aug 2026 06:34:05 -0400

IDEXX Labs (NASDAQ: IDXX) reported Q2 EPS of $4.27, $0.31 better than the analyst estimate of $3.96. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.2 billion.

GUIDANCE:

IDEXX Labs sees FY2026 EPS of $14.69-$14.94, versus the consensus of $14.66. IDEXX Labs sees FY2026 revenue of $4.7-4.75 billion, versus the consensus of $4.71 billion.

For earnings history and earnings-related data on IDEXX Labs (IDXX) click here.

Form 8-K IDEXX LABORATORIES INC For: Aug 04

Tue, 04 Aug 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260804/26860992.html

Form 8-K IDEXX LABORATORIES INC For: Aug 04

Tue, 04 Aug 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260804/26860992.html

IDEXX Laboratories Announces Second Quarter Results

Tue, 04 Aug 2026 06:30:00 -0400

Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.
Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization.
IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.
Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis.
Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5

IDEXX Laboratories Announces Second Quarter Results

Tue, 04 Aug 2026 06:30:00 -0400

Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.

Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization.

IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.

Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis.

Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5

IDEXX Laboratories Announces Second Quarter Results

Tue, 04 Aug 2026 06:30:00 -0400

Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.

Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization.

IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.

Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis.

Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5

IDEXX Laboratories Announces Second Quarter Results

Tue, 04 Aug 2026 06:30:00 -0400

Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.

Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization.

IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.

Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis.

Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5

IDEXX Laboratories Announces Second Quarter Results

Tue, 04 Aug 2026 06:30:00 -0400

Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.

Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization.

IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.

Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis.

Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5

IDEXX Laboratories Announces Second Quarter Results

Tue, 04 Aug 2026 06:30:00 -0400

Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.

Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization.

IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.

Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis.

Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5

IDEXX Laboratories Announces Second Quarter Results

Tue, 04 Aug 2026 06:30:00 -0400

Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.

Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization.

IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.

Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis.

Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5